Pliant Therapeutics Statistics
Total Valuation
PLRX has a market cap or net worth of $90.24 million. The enterprise value is -$158.92 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PLRX has 61.39 million shares outstanding. The number of shares has increased by 1.76% in one year.
| Current Share Class | 61.39M |
| Shares Outstanding | 61.39M |
| Shares Change (YoY) | +1.76% |
| Shares Change (QoQ) | +0.61% |
| Owned by Insiders (%) | 3.04% |
| Owned by Institutions (%) | 90.12% |
| Float | 50.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.34 |
| P/TBV Ratio | 0.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.03, with a Debt / Equity ratio of 0.23.
| Current Ratio | 11.03 |
| Quick Ratio | 10.90 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -69.54 |
Financial Efficiency
Return on equity (ROE) is -63.22% and return on invested capital (ROIC) is -36.28%.
| Return on Equity (ROE) | -63.22% |
| Return on Assets (ROA) | -33.89% |
| Return on Invested Capital (ROIC) | -36.28% |
| Return on Capital Employed (ROCE) | -74.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.28M |
| Employee Count | 171 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.36% in the last 52 weeks. The beta is 1.44, so PLRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | -89.36% |
| 50-Day Moving Average | 1.48 |
| 200-Day Moving Average | 9.39 |
| Relative Strength Index (RSI) | 43.19 |
| Average Volume (20 Days) | 719,890 |
Short Selling Information
The latest short interest is 5.15 million, so 8.39% of the outstanding shares have been sold short.
| Short Interest | 5.15M |
| Short Previous Month | 5.09M |
| Short % of Shares Out | 8.39% |
| Short % of Float | 10.22% |
| Short Ratio (days to cover) | 4.85 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -234.91M |
| Pretax Income | n/a |
| Net Income | -219.52M |
| EBITDA | -232.85M |
| EBIT | -234.91M |
| Earnings Per Share (EPS) | -$3.61 |
Full Income StatementBalance Sheet
The company has $305.65 million in cash and $60.17 million in debt, giving a net cash position of $245.47 million or $4.00 per share.
| Cash & Cash Equivalents | 305.65M |
| Total Debt | 60.17M |
| Net Cash | 245.47M |
| Net Cash Per Share | $4.00 |
| Equity (Book Value) | 257.16M |
| Book Value Per Share | 4.19 |
| Working Capital | 282.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$174.10 million and capital expenditures -$2.62 million, giving a free cash flow of -$176.71 million.
| Operating Cash Flow | -174.10M |
| Capital Expenditures | -2.62M |
| Free Cash Flow | -176.71M |
| FCF Per Share | -$2.88 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |